Jenny Harrington, CEO, Gilman Hill Asset Management Organon OGN-N BUY Jul 14, 2023

Spun off from Merck two years, but has been sitting in the penalty box. Pays a 5.5% dividend at 5x earnings.

Jenny Harrington, CEO, Gilman Hill Asset Management

Unknown

Unlock Rating

$20.585

Stock price when the opinion was issued

Pharma & Healthcare

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

It has no growth.

DON'T BUY

Recently on a downward trend. Fundamentally scores 3/10. Would not recommend buying. Price target falling. Has not been able to beat earnings. Better options available for investors. High debt levels not good for dividend outlook.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Jenny Harrington, CEO, Gilman Hill Asset Management Organon OGN-N BUY Jul 14, 2023

You might be interested:

Organon(OGN-N)

Organon(OGN-N)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Stockchase Insights

Jim Cramer - Mad Money

Dan Rohinton

Richard Fogler

The Panic-Proof Portfolio (Stockchase Research)